Company news
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) news
Every Amylyx Pharmaceuticals, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock
August 19, 2026
Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock
August 18, 2026
Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia
August 18, 2026
Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia o...
August 17, 2026
Amylyx Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
August 3, 2026
Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026
June 23, 2026
Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026
June 8, 2026
Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical...
May 15, 2026
Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results
May 7, 2026
Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia
May 5, 2026
Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
April 30, 2026
Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
April 8, 2026
Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypog...
March 24, 2026
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
March 3, 2026
Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026
February 24, 2026
Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identifie...
January 8, 2026
Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial
December 5, 2025
Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results
November 6, 2025
Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences
November 3, 2025
Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
October 30, 2025
Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock
September 10, 2025
Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock
September 9, 2025
Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP)
August 27, 2025
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
August 26, 2025
Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results
August 7, 2025
Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025
July 31, 2025
Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypogly...
July 13, 2025
Amylyx Pharmaceuticals to Host Event to Discuss Post-bariatric Hypoglycemia and Avexitide at ENDO 2025
July 8, 2025
Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis
June 3, 2025
Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences
May 21, 2025
Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome
May 12, 2025
Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results
May 8, 2025
Amylyx Pharmaceuticals to Participate in Upcoming May Investor Conferences
May 7, 2025
Amylyx Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025
May 1, 2025
Amylyx Pharmaceuticals Announces First Participant Dosed in Pivotal Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric Hypoglycemia
April 30, 2025
Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living wit...
April 9, 2025
Amylyx Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
April 2, 2025
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
March 4, 2025
Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences
February 25, 2025
Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025
February 24, 2025
Amylyx Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 10, 2025
Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Late...
January 21, 2025
Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
January 10, 2025
Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer
January 6, 2025
Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypogl...
December 4, 2024
Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference
November 27, 2024
Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results
November 7, 2024
Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024
November 4, 2024
Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AM...
October 17, 2024
Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on Oct...
October 15, 2024